Skip to main content

Living autologous heart valves for minimally invasive implantable procedures

Cel

Cardiovascular disease still represents the Killer No.1 in the EU accounting for substantial morbidity/mortality and health care cost. Heart valve replacement represents the most common surgical therapy for valvular heart disease with almost 200.000 annual implantations worldwide. Currently, heart valve prosthesis-associated problems occur in 30-35% of patients within 10 years, frequently necessitating risky re-operations. A particularly severe problem relates to children with congenital heart defects (1% of all newborns) who cannot be treated efficiently due to the lack of growths of the clinically available “artificial” valve prostheses. The principal objective of the LifeValve project is to develop a new therapeutic strategy to treat heart valve disease patients more efficiently. Two novel life science technologies will be combined: tissue engineering and minimally invasive implantation technology. In particular, the scientific and technological approach of the LifeValve project is to develop a clinically relevant tissue engineered living heart valve, with the capacity of regeneration and growths which can be implanted by minimally invasive catheter technology. First clinical trials will be enrolled in paediatric patients addressing the currently unmet dramatic medical need for growing implants. A highly interdisciplinary approach combines basic sciences, medical research, engineering and clinical practice. In addition, close industry-academia collaborations are integrated. It is expected that new knowledge applicable for a much broader field of cardiovascular diseases will be generated by the unique combination of consortium partners each representing opinion leaders in their fields. The consortium is compact comprising all the necessary expertise and skills to realize the precisely planned work in a short period of time.The close collaboration of the well interconnected LifeValve consortium will most efficiently contribute to an added value for the EU.

Zaproszenie do składania wniosków

FP7-HEALTH-2009-single-stage
Zobacz inne projekty w ramach tego zaproszenia

System finansowania

CP-IP - Large-scale integrating project

Koordynator

University of Zurich
Adres
Ramistrasse 71
8006 Zurich
Szwajcaria
Rodzaj działalności
Higher or Secondary Education Establishments
Wkład UE
€ 2 470 000
Kontakt administracyjny
Simon Philipp Hoerstrup (Prof.)

Uczestnicy (7)

DEUTSCHES HERZZENTRUM BERLIN
Niemcy
Wkład UE
€ 3 142 372
Adres
Augustenburger Platz 1
13353 Berlin
Rodzaj działalności
Higher or Secondary Education Establishments
Kontakt administracyjny
Boris Schmitt (Dr.)
TECHNISCHE UNIVERSITEIT EINDHOVEN
Niderlandy
Wkład UE
€ 1 784 000
Adres
Groene Loper 3
5612 AE Eindhoven
Rodzaj działalności
Higher or Secondary Education Establishments
Kontakt administracyjny
Frank Baaijens (Prof.)
MEDIZINISCHE UNIVERSITAET WIEN
Austria
Wkład UE
€ 215 480
Adres
Spitalgasse 23
1090 Wien
Rodzaj działalności
Higher or Secondary Education Establishments
Kontakt administracyjny
Gerald Maurer (Prof.)
pfm Produkte fur die Medizin AG
Niemcy
Wkład UE
€ 201 000
Adres
Wankelstr. 60
50996 Cologne
Rodzaj działalności
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt administracyjny
Jens Nikelski (Mr.)
XELTIS AG
Szwajcaria
Wkład UE
€ 850 500
Adres
Muhlebachstrasse 26
8008 Zurich
Rodzaj działalności
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt administracyjny
René Stenger (Mr.)
XELTIS BV
Niderlandy
Wkład UE
€ 1 146 000
Adres
De Lismortel R2 06 Cat Build 31
5612 AR Eindhoven
Rodzaj działalności
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt administracyjny
Martijn Cox (Mr.)
DEBRECENI EGYETEM
Węgry
Wkład UE
€ 67 000
Adres
Egyetem Ter 1
4032 Debrecen
Rodzaj działalności
Higher or Secondary Education Establishments
Kontakt administracyjny
Laszlo Balkay (Dr.)